Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

NCT03225924 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Stop of drug development

Conditions

DLBCL

Interventions

DRUG: Entospletinib
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone

Sponsor

The Lymphoma Academic Research Organisation